Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.

American journal of ophthalmology - 1 Mar 2016

Shah Anjali R, Williams Steven, Baumal Caroline R, Rosner Bernard, Duker Jay S, Seddon Johanna M

Abstract excerpt

PURPOSE: To identify factors that influence visual and anatomic response to treatment with intravitreal anti-vascular endothelial growth factor (VEGF) for neovascular age-related macular degeneration (AMD). DESIGN: Observational cohort study. METHODS: Seventy-two patients were included in this study. Best-corrected Snellen visual acuity (VA) and central foveal thickness measured on optical coherence tomography...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Bevacizumab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Choroidal Neovascularization

Share to Complement Factor H

Share to Intravitreal Injections

Share to Tomography, Optical Coherence

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Open in PubMed Open full text

Identifiers

PMID: 26705092
DOI: 10.1016/j.ajo.2015.11.033
PMCID: PMC6609150

Genes

CFH

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictors of Response to Intravitreal Anti-Vascular Endothelial Growth Factor Treatment of Age-Related Macular Degeneration.PMID 26705092Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Association of the Complement Factor H Y402H Polymorphism and Response to Anti-Vascular Endothelial Growth Factor Treatment in Age-Related Macular Degeneration: An Updated Meta-Analysis.Semantic proximity Read ↗

Genetic predictive biomarkers of anti-VEGF treatment response in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors.Semantic proximity Read ↗

Nongenetic risk factors for neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic associations of anti-vascular endothelial growth factor therapy response in age-related macular degeneration: a systematic review and meta-analysis.Semantic proximity Read ↗

A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degenerationSemantic proximity Read ↗

Pharmacogenetic associations with vascular endothelial growth factor inhibition in participants with neovascular age-related macular degeneration in the IVAN Study.Semantic proximity Read ↗

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.Semantic proximity Read ↗

Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration.Semantic proximity Read ↗

Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab.Semantic proximity Read ↗

How do genetic polymorphisms influence the efficacy of age-related macular degeneration treatments? A systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.